AA
CRBP icon

ALPS Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

ALPS Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,298
Closed -$628K – 823
2019
Q3 		$628K Sell
4,298
-199
-4% -$34.7K ﹤0.01% 448
2019
Q2 		$935K Sell
4,497
-546
-11% -$117K 0.01% 343
2019
Q1 		$1.05M Buy
5,043
+634
+14% +$140K 0.01% 314
2018
Q4 		$772K Buy
4,409
+1,035
+31% +$207K 0.01% 361
2018
Q3 		$764K Buy
3,374
+610
+22% +$98.6K 0.01% 450
2018
Q2 		$419K Buy
+2,764
New +$502K ﹤0.01% 735
2017
Q4 		– Sell
-1,649
Closed -$354K – 852
2017
Q3 		$354K Buy
1,649
+138
+9% +$27K ﹤0.01% 712
2017
Q2 		$286K Buy
+1,511
New +$296K ﹤0.01% 725

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ALPS Advisors's CRBP Position: Q4 2019 in Review

ALPS Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q4 2019, closing a stake of 4,298 shares — an estimated $628K sold.

ALPS Advisors first reported a position in CRBP in Q2 2017 and held it in 8 quarters. The position peaked at $1.05M in Q1 2019. 105 funds tracked by Wall St. Rank hold CRBP as of Q4 2019.

  • ALPS Advisors reported no remaining Corbus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • ALPS Advisors sold 4,298 Corbus Pharmaceuticals shares in Q4 2019, an estimated $628K.
  • ALPS Advisors first reported a position in Corbus Pharmaceuticals in Q2 2017 and held it in 8 quarters.
  • ALPS Advisors's Corbus Pharmaceuticals position peaked at $1.05M in Q1 2019.
  • 105 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2019.

Based on ALPS Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.